{"entity":{"id":"nct04106492","kind":"trial","name":"SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a)","aka":["SQ3370-001","Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors"],"tldr":"Described by its investigators as the first use of click chemistry inside patients. A gel was injected into one tumour and an inactive form of doxorubicin was given into a vein, to be switched on at the gel. Doses far above the usual doxorubicin dose were tolerated, but tumours shrank in 2 of 14 sarcoma patients, no more often than with ordinary doxorubicin, and the sponsor stopped the trial.","summary":"A multicentre, open-label, non-randomised phase 1/2a study sponsored by Shasqi, registered in September 2019 and started on 1 August 2020 at seven centres in the United States and three in Australia. Each 21-day cycle began with 10 or 20 mL of the biopolymer SQL70 injected into a single lesion, followed by the doxorubicin prodrug SQP33 infused daily. The registry lists nine dose-escalation cohorts from 8 to 315 mg/m2 of SQP33 a day for five days with 10 mL of SQL70, two cohorts with 20 mL, one further cohort at 185 mg/m2 a day (Cohort A) and three phase 2a groups, 53 participants in all.\n\nPhase 1 set out to find the recommended phase 2 dose, which the posted results give as 1250 mg/m2 of SQP33 per cycle. The preprint reporting the whole trial describes 39 phase 1 patients treated at 0.38 to 15 times the standard doxorubicin dose with no dose-limiting toxicity, and 12 times chosen as the recommended dose.\n\nPhase 2a tested that dose in soft tissue sarcoma on three-day and five-day schedules. The registry's response table shows objective responses in 2 of 15 participants: none of 1 in a cohort below the recommended dose, 1 of 2 in the extremity sarcoma group, none of 6 on the three-day schedule and 1 of 6 on the five-day schedule. The preprint reports an unconfirmed objective response rate of 14.3 per cent (2 of 14) and disease control in 71.4 per cent (10 of 14; 95% CI 41.9 to 91.6), with tumour shrinkage in injected and non-injected lesions.\n\nThe registry records the study as terminated by the sponsor's decision, with primary completion on 7 September 2023. The preprint gives the reason: the prespecified criterion for continuing, a response rate greater than that of standard doxorubicin, was not met. Across all 53 participants the registry reports 2 deaths from any cause and 15 people with at least one serious adverse event over the one-year reporting period.","status":"mixed","asOf":"2026-11-16","links":[{"label":"ClinicalTrials.gov NCT04106492","url":"https://clinicaltrials.gov/study/NCT04106492"},{"label":"ClinicalTrials.gov: posted results","url":"https://clinicaltrials.gov/study/NCT04106492?tab=results"},{"label":"Chawla et al., medRxiv 2025 (preprint)","url":"https://doi.org/10.1101/2025.06.02.25328445"},{"label":"Srinivasan et al., Clinical Cancer Research 2025","url":"https://doi.org/10.1158/1078-0432.CCR-24-2539"},{"label":"Bui et al., ASCO 2024 abstract 11555","url":"https://doi.org/10.1200/JCO.2024.42.16_suppl.11555"}],"tags":["failure"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["click-activated-prodrugs"],"targets":[],"drugs":["sq3370"],"companies":["shasqi"],"institutions":["sarcoma-oncology-center","md-anderson","city-of-hope","chris-obrien-lifehouse"],"pathways":[],"terms":["rp2d","dose-limiting-toxicity","orr"],"trials":[],"people":["sant-chawla"],"bottlenecks":[],"keyPapers":["paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025","paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025"],"journals":[],"dependsOn":[],"notes":["The registry's stated reason for stopping is \"Sponsor's decision\"; the response criterion is the reason given in the investigators' preprint.","The registry and the preprint count the phase 2a response population differently (15 and 14); both report two responses.","Results were first posted on ClinicalTrials.gov on 14 November 2025. The planned interim analysis was presented at ASCO 2024 (abstract 11555), with the same response rate."],"provenance":{"editedBy":"OnCo (company site, ClinicalTrials.gov v2, Crossref, Europe PMC, NIH RePORTER)","editedOn":"2026-11-16"},"nct":"NCT04106492","phase":"1/2","setting":"Adults with locally advanced or metastatic solid tumours that could be injected (phase 1), then anthracycline-naive adults with unresectable or metastatic soft tissue sarcoma (phase 2a)","sponsor":"Shasqi, Inc.","result":"Recommended phase 2 dose 1250 mg/m2 of SQP33 per cycle, with no dose-limiting toxicity up to 15 times the standard doxorubicin dose. In phase 2a, 2 of 14 patients with soft tissue sarcoma had an unconfirmed objective response (14.3 per cent), comparable to standard doxorubicin; the trial was stopped because its prespecified response criterion was not met.","started":"2020-08-01","startedType":"actual","yearReported":2025,"enrolled":53,"enrolledBasis":"registry","outcomes":[{"endpoint":"Recommended phase 2 dose of SQP33 (phase 1)","primary":true,"unit":"mg/m2 per cycle","arms":[{"name":"Dose escalation with 10 mL SQL70","n":30,"value":1250},{"name":"Dose escalation with 20 mL SQL70","n":8,"value":1250}],"source":"https://clinicaltrials.gov/study/NCT04106492?tab=results"},{"endpoint":"Participants with an objective response (phase 2a, RECIST, by MRI)","unit":"participants","arms":[{"name":"Cohort A, 185 mg/m2 a day (below the recommended dose)","n":1,"value":0},{"name":"Phase 2a group 1, extremity soft tissue sarcoma","n":2,"value":1},{"name":"Phase 2a group 2, three-day schedule","n":6,"value":0},{"name":"Phase 2a group 2, five-day schedule","n":6,"value":1}],"source":"https://clinicaltrials.gov/study/NCT04106492?tab=results"},{"endpoint":"Unconfirmed objective response rate, soft tissue sarcoma at the recommended dose (preprint)","unit":"percent","arms":[{"name":"SQ3370 phase 2a","n":14,"value":14.3,"note":"2 of 14"}],"source":"https://doi.org/10.1101/2025.06.02.25328445"},{"endpoint":"Disease control rate, soft tissue sarcoma at the recommended dose (preprint)","unit":"percent","arms":[{"name":"SQ3370 phase 2a","n":14,"value":71.4,"note":"10 of 14; 95% CI 41.9 to 91.6"}],"source":"https://doi.org/10.1101/2025.06.02.25328445"}],"replication":"None. This is the only registered trial of SQ3370 and the only human study of this click-activated design; it had no comparison arm."},"route":"/trials/nct04106492/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"technology":[{"id":"click-activated-prodrugs","kind":"technology","name":"Click-activated prodrugs (bioorthogonal drug activation in the body)","route":"/technologies/click-activated-prodrugs/"}],"drug":[{"id":"sq3370","kind":"drug","name":"SQ3370","route":"/drugs/sq3370/"}],"company":[{"id":"shasqi","kind":"company","name":"Shasqi","route":"/companies/shasqi/"}],"institution":[{"id":"chris-obrien-lifehouse","kind":"institution","name":"Chris O'Brien Lifehouse","route":"/institutions/chris-obrien-lifehouse/"},{"id":"city-of-hope","kind":"institution","name":"City of Hope","route":"/institutions/city-of-hope/"},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"},{"id":"sarcoma-oncology-center","kind":"institution","name":"Sarcoma Oncology Center","route":"/institutions/sarcoma-oncology-center/"}],"term":[{"id":"dose-limiting-toxicity","kind":"term","name":"Dose-limiting toxicity (DLT)","route":"/terms/dose-limiting-toxicity/"},{"id":"orr","kind":"term","name":"Objective response rate (ORR)","route":"/terms/orr/"},{"id":"rp2d","kind":"term","name":"Recommended phase 2 dose (RP2D)","route":"/terms/rp2d/"}],"person":[{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/"}],"paper":[{"id":"paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025","kind":"paper","name":"SQ3370 from preclinical evaluation to a first-in-human dose-escalation trial: the first click chemistry-based cancer therapeutic","route":"/key-papers/paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025/"},{"id":"paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025","kind":"paper","name":"SQ3370 phase 1/2a results in advanced solid tumours and soft tissue sarcoma (preprint)","route":"/key-papers/paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025/"}]}}